Networking Biomedical Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid, Spain
Ramón y Cajal Institute of Sanitary Research (IRYCIS), Madrid, Spain
University Center of Defense of Madrid (CUD-ACD), Madrid, Spain
Search for other papers by Natalio García-Honduvilla in
Google Scholar
PubMed
Networking Biomedical Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid, Spain
Ramón y Cajal Institute of Sanitary Research (IRYCIS), Madrid, Spain
Search for other papers by Alberto Cifuentes in
Google Scholar
PubMed
Networking Biomedical Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid, Spain
Ramón y Cajal Institute of Sanitary Research (IRYCIS), Madrid, Spain
Search for other papers by Miguel A Ortega in
Google Scholar
PubMed
Search for other papers by Marta Pastor in
Google Scholar
PubMed
Search for other papers by Garazi Gainza in
Google Scholar
PubMed
Search for other papers by Eusebio Gainza in
Google Scholar
PubMed
Networking Biomedical Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid, Spain
Ramón y Cajal Institute of Sanitary Research (IRYCIS), Madrid, Spain
University Center of Defense of Madrid (CUD-ACD), Madrid, Spain
Search for other papers by Julia Buján in
Google Scholar
PubMed
Networking Biomedical Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid, Spain
Ramón y Cajal Institute of Sanitary Research (IRYCIS), Madrid, Spain
University Center of Defense of Madrid (CUD-ACD), Madrid, Spain
Immune System Diseases-Rheumatology and Oncology Service, University Hospital Príncipe de Asturias, Alcalá de Henares, Madrid, Spain
Search for other papers by Melchor Álvarez-Mon in
Google Scholar
PubMed
of rhEGF have not been established. Furthermore, the potential effects of the intralesional rhEGF administration in the local inflammatory-immune response remain unknown ( 19 , 20 , 21 ). The aim of the present work was to study of the effects of
Beijing Key Laboratory of Diabetes Research and Care, Beijing, China
Search for other papers by Xiaoxia Jia in
Google Scholar
PubMed
Beijing Key Laboratory of Diabetes Research and Care, Beijing, China
Search for other papers by Yaxin An in
Google Scholar
PubMed
Beijing Key Laboratory of Diabetes Research and Care, Beijing, China
Search for other papers by Yuechao Xu in
Google Scholar
PubMed
Beijing Key Laboratory of Diabetes Research and Care, Beijing, China
Search for other papers by Yuxian Yang in
Google Scholar
PubMed
Beijing Key Laboratory of Diabetes Research and Care, Beijing, China
Search for other papers by Chang Liu in
Google Scholar
PubMed
Beijing Key Laboratory of Diabetes Research and Care, Beijing, China
Search for other papers by Dong Zhao in
Google Scholar
PubMed
Beijing Key Laboratory of Diabetes Research and Care, Beijing, China
Search for other papers by Jing Ke in
Google Scholar
PubMed
enrolled at the Metabolism and Immune Disease Center of Beijing Luhe Hospital, Capital Medical University from September 2019 to December 2019. A total of 234 patients with T2DM including 116 females and 118 males were included. The diagnosis of T2DM was
Beijing Key Laboratory of Diabetes Research and Care, Beijing, China
Search for other papers by Rong Xu in
Google Scholar
PubMed
Beijing Key Laboratory of Diabetes Research and Care, Beijing, China
Search for other papers by Difei Lian in
Google Scholar
PubMed
Beijing Key Laboratory of Diabetes Research and Care, Beijing, China
Search for other papers by Yan Xie in
Google Scholar
PubMed
Beijing Key Laboratory of Diabetes Research and Care, Beijing, China
Search for other papers by Lin Mu in
Google Scholar
PubMed
Beijing Key Laboratory of Diabetes Research and Care, Beijing, China
Search for other papers by Yali Wu in
Google Scholar
PubMed
Beijing Key Laboratory of Diabetes Research and Care, Beijing, China
Search for other papers by Zhilei Chen in
Google Scholar
PubMed
Beijing Key Laboratory of Diabetes Research and Care, Beijing, China
Search for other papers by Baoyu Zhang in
Google Scholar
PubMed
with osteoporosis and mechanistic insights into its effect on bone metabolism . Endocrine, Metabolic and Immune Disorders Drug Targets 2019 19 259 – 273 . ( https://doi.org/10.2174/1871530318666181102115106 ) 5 Dalbeth N Gosling AL Gaffo A
Search for other papers by A Rouland in
Google Scholar
PubMed
INSERM Unit, LNC-UMR 1231, University of Burgundy, Dijon, France
Search for other papers by J-C Chauvet-Gelinier in
Google Scholar
PubMed
INSERM Unit, LNC-UMR 1231, University of Burgundy, Dijon, France
Search for other papers by A-L Sberna in
Google Scholar
PubMed
Search for other papers by E Crevisy in
Google Scholar
PubMed
Search for other papers by P Buffier in
Google Scholar
PubMed
Search for other papers by T Mouillot in
Google Scholar
PubMed
INSERM Unit, LNC-UMR 1231, University of Burgundy, Dijon, France
Search for other papers by J-M Petit in
Google Scholar
PubMed
INSERM Unit, LNC-UMR 1231, University of Burgundy, Dijon, France
Search for other papers by B Vergès in
Google Scholar
PubMed
is an auto-immune disease whereas T2D is not. Many data indicate that stress could be a trigger factor for the onset of auto-immune diseases, and several studies suggest that stress is not only a participating factor, but can, in fact, cause disease
Search for other papers by Bliss Anderson in
Google Scholar
PubMed
Search for other papers by Daniel L Morganstein in
Google Scholar
PubMed
Introduction Immunotherapy with immune checkpoint inhibitors (CPI’s) has been revolutionising the management of advanced malignancies with their success in improving overall patient survival ( 1 , 2 ). CPI’s are antibodies that block T
School of Nursing, Institute of Clinical Sciences, University of Birmingham, Edgbaston, Birmingham, UK
Search for other papers by Jane Fletcher in
Google Scholar
PubMed
Search for other papers by Emma L Bishop in
Google Scholar
PubMed
Search for other papers by Stephanie R Harrison in
Google Scholar
PubMed
Search for other papers by Amelia Swift in
Google Scholar
PubMed
Search for other papers by Sheldon C Cooper in
Google Scholar
PubMed
Search for other papers by Sarah K Dimeloe in
Google Scholar
PubMed
Search for other papers by Karim Raza in
Google Scholar
PubMed
Search for other papers by Martin Hewison in
Google Scholar
PubMed
circulation include 3epi-25D and sulphated and glucuronide forms of 25D. Intracrine synthesis of 1,25D from 25D in tissues such as the placenta, spleen (immune system) and lungs is associated with immunomodulatory effects. Endocrine synthesis of 1,25D in the
Search for other papers by Jaafar Jaafar in
Google Scholar
PubMed
Search for other papers by Eugenio Fernandez in
Google Scholar
PubMed
Search for other papers by Heba Alwan in
Google Scholar
PubMed
Search for other papers by Jacques Philippe in
Google Scholar
PubMed
Introduction A paradigm shift in the landscape of cancer treatment is in progress. Immune checkpoint inhibitors (ICIs) have emerged as new arms in the panoply of antitumor therapy. Nowadays, the interest in ICIs, such as programmed cell death
Search for other papers by Anne H van der Spek in
Google Scholar
PubMed
Search for other papers by Olga V Surovtseva in
Google Scholar
PubMed
Search for other papers by Saskia Aan in
Google Scholar
PubMed
Search for other papers by Anton T J Tool in
Google Scholar
PubMed
Search for other papers by Annemarie van de Geer in
Google Scholar
PubMed
Search for other papers by Korcan Demir in
Google Scholar
PubMed
Search for other papers by Anja L M van Gucht in
Google Scholar
PubMed
Search for other papers by A S Paul van Trotsenburg in
Google Scholar
PubMed
Search for other papers by Timo K van den Berg in
Google Scholar
PubMed
Search for other papers by Eric Fliers in
Google Scholar
PubMed
Search for other papers by Anita Boelen in
Google Scholar
PubMed
phagocytic cells of the innate immune system. Neutrophils are the most abundant circulating leukocytes and, as the first cells to migrate to the site of infection, play an essential role in bacterial killing ( 22 , 23 ). Macrophages are essential for the
Cardiff University School of Medicine, Cardiff, UK
Search for other papers by Hei Yi Vivian Pak in
Google Scholar
PubMed
Search for other papers by Andrew Lansdown in
Google Scholar
PubMed
Centre for Diabetes and Endocrinology, University Hospital of Wales, Cardiff, UK
Search for other papers by Peter Taylor in
Google Scholar
PubMed
Neuroscience and Mental Health Research Institute, Cardiff University, Cardiff, UK
Search for other papers by Dafydd Aled Rees in
Google Scholar
PubMed
Search for other papers by John Stephen Davies in
Google Scholar
PubMed
Cardiff University School of Medicine, Cardiff, UK
Search for other papers by Caroline Hayhurst in
Google Scholar
PubMed
Objective
Acromegaly is a rare condition and there is often a long path to diagnosis for many patients. We sought to explore patient’s perceptions and understanding of acromegaly, to examine the quality of communication and find gaps in the information provided at diagnosis.
Design
A prospective study using qualitative research methodology and grounded theory. A semi-structured interview was conducted with 18 patients treated for acromegaly in a single tertiary centre and verbatim transcripts were thematically analysed for overarching themes.
Results
Eighteen patients with acromegaly were interviewed. The mean age of participants was 52 (range 30–72). Four overarching themes emerged; (1) Patients rely on online resources to understand acromegaly in the time between diagnosis and tertiary care clinic; (2) There is not enough support available for patients; (3) Patients have a basic understanding of acromegaly and associated conditions, but the long-term impact is underestimated; and (4) Patients initially felt intimidated by the multidisciplinary team panel, but overall found it useful.
Conclusion
Acromegalic patients have a strong need for information at the point of initial diagnosis, in particular online resources and interaction with other experienced patients. Wider dissemination of patient educational resources into primary and secondary care settings may improve overall patient satisfaction, treatment adherence and subsequent health care provider–patient relationships.
Search for other papers by Zhenyu Liu in
Google Scholar
PubMed
Search for other papers by Huixi Kong in
Google Scholar
PubMed
Search for other papers by Baoyu Zhang in
Google Scholar
PubMed
To optimize the treatment plan for patients with type 2 diabetes mellitus (T2DM) and hyperuricemia, this narrative literature review summarizes the effect of antidiabetic drugs on serum uric acid (SUA) levels using data from observational studies, prospective clinical trials, post hoc analyses, and meta-analyses. SUA is an independent risk factor for T2DM, and evidence has shown that patients with both gout and T2DM exhibit a mutually interdependent effect on higher incidences. We find that insulin and dipeptidyl peptidase 4 inhibitor (DPP-4i) except linagliptin could increase the SUA and other drugs including metformin, thiazolidinediones (TZDs), glucagon-like peptide-1 receptor agonists (GLP-1 RAs), linagliptin, sodium–glucose cotransporter 2 inhibitors (SGLT2i), and α-glucosidase inhibitors have a reduction effect on SUA. We explain the mechanisms of different antidiabetic drugs above on SUA and analyze them compared with actual data. For sulfonylureas, meglitinides, and amylin analogs, the underlying mechanism remains unclear. We think the usage of linagliptin and SGLT2i is the most potentially effective treatment of patients with T2DM and hyperuricemia currently. Our review is a comprehensive summary of the effects of antidiabetic drugs on SUA, which includes actual data, the mechanisms of SUA regulation, and the usage rate of drugs.
